140 related articles for article (PubMed ID: 37848297)
1. Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancreatic ductal adenocarcinoma.
Ponzini FM; Schultz CW; Leiby BE; Cannaday S; Yeo T; Posey J; Bowne WB; Yeo C; Brody JR; Lavu H; Nevler A
BMJ Open; 2023 Oct; 13(10):e073839. PubMed ID: 37848297
[TBL] [Abstract][Full Text] [Related]
2. The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria.
Schultz CW; McCarthy GA; Nerwal T; Nevler A; DuHadaway JB; McCoy MD; Jiang W; Brown SZ; Goetz A; Jain A; Calvert VS; Vishwakarma V; Wang D; Preet R; Cassel J; Summer R; Shaghaghi H; Pommier Y; Baechler SA; Pishvaian MJ; Golan T; Yeo CJ; Petricoin EF; Prendergast GC; Salvino J; Singh PK; Dixon DA; Brody JR
Mol Cancer Ther; 2021 Nov; 20(11):2166-2176. PubMed ID: 34413127
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial.
Reni M; Balzano G; Zanon S; Zerbi A; Rimassa L; Castoldi R; Pinelli D; Mosconi S; Doglioni C; Chiaravalli M; Pircher C; Arcidiacono PG; Torri V; Maggiora P; Ceraulo D; Falconi M; Gianni L
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):413-423. PubMed ID: 29625841
[TBL] [Abstract][Full Text] [Related]
4. Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial).
Lau SP; van 't Land FR; van der Burg SH; Homs MYV; Lolkema MP; Aerts JGJV; van Eijck CHJ
BMJ Open; 2022 Jun; 12(6):e060431. PubMed ID: 35710239
[TBL] [Abstract][Full Text] [Related]
5. MAPLE-PD trial (Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer during Pancreaticoduodenectomy): study protocol for a multicenter randomized controlled trial of 354 patients with pancreatic ductal adenocarcinoma.
Hirono S; Kawai M; Okada KI; Fujii T; Sho M; Satoi S; Amano R; Eguchi H; Mataki Y; Nakamura M; Matsumoto I; Baba H; Tani M; Kawabata Y; Nagakawa Y; Yamada S; Murakami Y; Shimokawa T; Yamaue H
Trials; 2018 Nov; 19(1):613. PubMed ID: 30409152
[TBL] [Abstract][Full Text] [Related]
6. Triple modal treatment comprising with proton beam radiation, hyperthermia, and gemcitabine/nab-paclitaxel for locally advanced pancreatic cancer: a phase I/II study protocol (TT-LAP trial).
Shimomura O; Endo M; Makishima H; Yamada T; Hashimoto S; Numajiri H; Miyazaki Y; Doi M; Furuya K; Takahashi K; Moriwaki T; Hasegawa N; Yamamoto Y; Niisato Y; Kobayashi M; Mizumoto M; Nakai K; Saito T; Hoshiai S; Saida T; Mathis BJ; Mori K; Nakajima T; Tsuchiya K; Sakurai H; Oda T
BMC Cancer; 2023 Jul; 23(1):624. PubMed ID: 37403011
[TBL] [Abstract][Full Text] [Related]
7. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.
Shui L; Cheng K; Li X; Shui P; Zhou X; Li J; Yi C; Cao D
BMC Cancer; 2020 Jul; 20(1):636. PubMed ID: 32646394
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B
Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639
[TBL] [Abstract][Full Text] [Related]
9. Multicenter randomized controlled trial and registry study to assess the safety and efficacy of the NanoKnife® system for the ablation of stage 3 pancreatic adenocarcinoma: overview of study protocols.
Narayanan G; Bilimoria MM; Hosein PJ; Su Z; Mortimer KM; Martin RCG
BMC Cancer; 2021 Jul; 21(1):785. PubMed ID: 34233640
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer.
Kocher HM; Basu B; Froeling FEM; Sarker D; Slater S; Carlin D; deSouza NM; De Paepe KN; Goulart MR; Hughes C; Imrali A; Roberts R; Pawula M; Houghton R; Lawrence C; Yogeswaran Y; Mousa K; Coetzee C; Sasieni P; Prendergast A; Propper DJ
Nat Commun; 2020 Sep; 11(1):4841. PubMed ID: 32973176
[TBL] [Abstract][Full Text] [Related]
11. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma.
Cui J; Yang H; Liu J; Chen D; Hu J; Zhang H; Wang Y; Han T; Mao T; Jiao F; Biskup E; Pan Y; Liu M; Wang L
BMC Cancer; 2021 Jun; 21(1):672. PubMed ID: 34098895
[TBL] [Abstract][Full Text] [Related]
13. Clinical trial protocol for PanDox: a phase I study of targeted chemotherapy delivery to non-resectable primary pancreatic tumours using thermosensitive liposomal doxorubicin (ThermoDox®) and focused ultrasound.
Spiers L; Gray M; Lyon P; Sivakumar S; Bekkali N; Scott S; Collins L; Carlisle R; Wu F; Middleton M; Coussios C
BMC Cancer; 2023 Sep; 23(1):896. PubMed ID: 37741968
[TBL] [Abstract][Full Text] [Related]
14. Tumour-specific fluorescence-guided surgery for pancreatic cancer using panitumumab-IRDye800CW: a phase 1 single-centre, open-label, single-arm, dose-escalation study.
Lu G; van den Berg NS; Martin BA; Nishio N; Hart ZP; van Keulen S; Fakurnejad S; Chirita SU; Raymundo RC; Yi G; Zhou Q; Fisher GA; Rosenthal EL; Poultsides GA
Lancet Gastroenterol Hepatol; 2020 Aug; 5(8):753-764. PubMed ID: 32416764
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-blind randomized phase II study.
Hashimoto D; Satoi S; Ishikawa H; Kodera Y; Kamei K; Hirano S; Fujii T; Uemura K; Tsuchida A; Yamada S; Yamamoto T; Hirota K; Sekimoto M
Trials; 2022 Feb; 23(1):135. PubMed ID: 35151367
[TBL] [Abstract][Full Text] [Related]
16. A Phase I Safety, Pharmacokinetic, and Pharmacodynamic Presurgical Trial of Vitamin E δ-tocotrienol in Patients with Pancreatic Ductal Neoplasia.
Springett GM; Husain K; Neuger A; Centeno B; Chen DT; Hutchinson TZ; Lush RM; Sebti S; Malafa MP
EBioMedicine; 2015 Dec; 2(12):1987-95. PubMed ID: 26844278
[TBL] [Abstract][Full Text] [Related]
17. PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer.
Douglas JE; Liu S; Ma J; Wolff RA; Pant S; Maitra A; Tamm EP; Bhosale P; Katz MHG; Varadhachary GR; Koay EJ
BMC Cancer; 2022 Jan; 22(1):14. PubMed ID: 34980020
[TBL] [Abstract][Full Text] [Related]
18. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC
Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731
[TBL] [Abstract][Full Text] [Related]
19. Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: study protocol for a multicentre randomised controlled trial.
Pan S; Qin T; Yin T; Yu X; Li J; Liu J; Zhao W; Chen X; Li D; Liu J; Li J; Liu Y; Zhu F; Wang M; Zhang H; Qin R;
BMJ Open; 2022 Apr; 12(4):e057128. PubMed ID: 35379633
[TBL] [Abstract][Full Text] [Related]
20. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
Wainberg ZA; Bekaii-Saab T; Boland PM; Dayyani F; Macarulla T; Mody K; Belanger B; Maxwell F; Moore Y; Thiagalingam A; Wang T; Zhang B; Dean A
Eur J Cancer; 2021 Jul; 151():14-24. PubMed ID: 33957442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
